Catalogo dei prodotti della ricerca

NOBILI, Valerio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.403
AS - Asia 1.333
EU - Europa 1.258
SA - Sud America 54
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 13.100
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.318
SG - Singapore 511
IN - India 451
SE - Svezia 301
CN - Cina 278
IT - Italia 276
RO - Romania 122
GB - Regno Unito 106
DE - Germania 99
IE - Irlanda 86
CA - Canada 74
FI - Finlandia 68
UA - Ucraina 68
RU - Federazione Russa 44
TR - Turchia 38
AR - Argentina 27
TG - Togo 24
BG - Bulgaria 20
NL - Olanda 20
BR - Brasile 18
ID - Indonesia 16
BE - Belgio 13
EU - Europa 8
FR - Francia 8
MX - Messico 8
KR - Corea 6
VN - Vietnam 6
AU - Australia 5
CH - Svizzera 5
DK - Danimarca 5
JP - Giappone 5
PK - Pakistan 5
CL - Cile 4
ES - Italia 4
PT - Portogallo 4
SC - Seychelles 4
TW - Taiwan 4
ZA - Sudafrica 4
BZ - Belize 3
GR - Grecia 3
IR - Iran 3
TN - Tunisia 3
EG - Egitto 2
IQ - Iraq 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
PE - Perù 2
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
GY - Guiana 1
HK - Hong Kong 1
LT - Lituania 1
MD - Moldavia 1
PH - Filippine 1
ZM - Zambia 1
Totale 13.100
Salva come PNG Salva come JPEG
Città #
Fairfield 2.068
Ashburn 863
Woodbridge 859
Seattle 809
Houston 722
Cambridge 687
Wilmington 619
Chandler 541
Ann Arbor 345
Singapore 312
Princeton 272
Millbury 246
Plano 241
Santa Clara 223
Des Moines 165
Lawrence 150
Beijing 136
San Diego 117
Rome 111
Falls Church 109
Dearborn 106
Dublin 86
Andover 74
Southend 72
Norwalk 59
Toronto 45
Istanbul 38
San Paolo di Civitate 36
Boston 28
Helsinki 26
Fremont 25
Mannheim 25
New York 25
Federal 24
Lomé 24
Ottawa 24
Falkenstein 23
Bühl 21
Moscow 21
Sofia 20
San Mateo 18
Jakarta 16
Redmond 16
Brussels 13
Jinan 13
Birmingham 11
Jacksonville 11
Buffalo 10
Hefei 10
Linköping 10
Nanjing 10
Guangzhou 9
Kunming 9
London 9
Phoenix 9
Shenzhen 9
Boardman 8
Laurel 8
Nanchang 8
Milan 7
San Jose 7
Ho Chi Minh City 6
Bremen 5
Chengdu 5
Fort Worth 5
Los Angeles 5
Mexico City 5
Redwood City 5
Candelo 4
Florence 4
Fuzhou 4
Hangzhou 4
New Taipei City 4
Palermo 4
Provo 4
Riva 4
Shenyang 4
Trumbull 4
Washington 4
Absecon 3
Belize City 3
Boydton 3
Coarezza 3
Foggia 3
Frankfurt am Main 3
Grafing 3
Jönköping 3
Las Vegas 3
Leawood 3
Lisbon 3
Montréal 3
Muizenberg 3
San Pablo 3
Sidi Bou Saïd 3
Torino 3
Westminster 3
Wuhan 3
Xian 3
Zhengzhou 3
Albuquerque 2
Totale 10.760
Salva come PNG Salva come JPEG
Nome #
Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease 106
Urinary 1H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment 99
Gut microbiota markers in obese adolescent and adult patients: Age-dependent differential patterns 97
ADAR enzyme and miRNA story: A nucleotide that can make the difference 92
Are children after liver transplant more prone to non-alcoholic fatty liver disease 92
The pharmacological management of NAFLD in children and adolescents 91
Pediatric liver diseases: current challenges and future perspectives 90
Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? 89
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis 85
Atherogenic dyslipidemia and cardiovascular risk factors in obese children 84
Aminotransferases as predictors of mortality 84
Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl 83
Laparoscopic sleeve gastrectomy improves nonalcoholic fatty liver disease-related liver damage in adolescents by reshaping cellular interactions and hepatic adipocytokine production 83
LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease 81
Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease? 81
A 360-degree overview of paediatric NAFLD: recent insights 81
Biochemical parameters and anthropometry predict nafld in obese children 79
Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease 78
The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis 77
Liver fibrosis in paediatric liver diseases 77
The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage 77
Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease. more than ectopic fat 76
Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis 75
Metabolic Syndrome and Alcohol Abuse: A Potential Hepatocarcinogenic Mix in Adolescents 75
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease 75
Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease 75
Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease 74
Paediatric non-alcoholic fatty liver disease: impact on patients and mothers' quality of life 74
Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies 73
Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach 73
Nonalcoholic Fatty Liver in Children and Adolescents: An Overview 72
Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease 71
Retinol-Binding Protein 4: A Promising Circulating Marker of Liver Damage in Pediatric Nonalcoholic Fatty Liver Disease 71
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial 71
Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease 70
The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease 70
Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease 70
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies 70
Treatment of chronic hepatitis c in children. is it necessary and, if so, in whom 70
Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease 70
Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children 70
Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease. double-blind randomised controlled clinical trial 70
Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis 69
Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma 69
Biomarkers in nonalcoholic fatty liver disease. a new era in diagnosis and staging of disease in children 69
Metabolic disorders: All that we know from circulating biomarkers 69
The contribution of the adipose tissue-liver axis in pediatric patients with nonalcoholic fatty liver disease after laparoscopic sleeve gastrectomy 69
Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease 68
Metabolic syndrome and nonalcoholic steatohepatitis recurrence after liver transplantation in children 68
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets 68
Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review 68
Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms 68
Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach 68
Programming, metabolic syndrome, and nafld. the challenge of transforming a vicious cycle into a virtuous cycle 67
Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment 67
Viral hepatitis in children 67
The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease 67
Performance of elf serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease 67
Insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLF) in obese paediatric patients. 66
Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage 66
Preemptive liver transplantation in a child with familial hypercholesterolemia 66
Extrahepatic portal vein thrombosis in children and adolescents. influence of genetic thrombophilic disorders 66
Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development 66
Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis 66
LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease 66
The use of ultrasound in clinical setting for children affected by NAFLD. is it safe and accurate? 66
Screening of an Echinococcus granulosus cDNA library with IgG4 from patients with cystic echinococcosis identifies a new tegumental protein involved in the immune escape. 65
The apoc3 t-455c and c-482t promoter region polymorphisms are not associated with the severity of liver damage independently of pnpla3 i148m genotype in patients with nonalcoholic fatty 65
Effect of treatment with polyunsaturated fatty acids on hcv- or diet-induced fatty liver 65
I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology 65
Insulin dynamics of breast- or formula-fed overweight and obese children 65
Human hepatic stellate cells are liver-resident antigen-presenting cells 64
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease 64
Toll-like receptor 4. a starting point for proinflammatory signals in fatty liver disease 64
Hepatic stem cells and adipocytokines in nonalcoholic fatty liver disease pediatric patients after laparoscopic sleeve gastrectomy 64
null 64
Metformin use in children with nonalcoholic fatty liver disease. an open-label, 24-month, observational pilot study 64
The wide spectrum of hepatic iron overload 64
Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease 64
Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review 63
Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children 63
Use of metformin in pediatric age 63
Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease 63
Children unresponsive to hepatitis B Virus vaccination also need celiac disease testing 63
Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease 63
Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease 62
The development of the Pediatric NAFLD Fibrosis Score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease 62
Supplementation of monounsaturated and polyunsaturated fatty acids in non-alcoholic fatty liver disease and metabolic syndrome 62
Pediatric post-transplant metabolic syndrome: new clouds on the horizon 62
Association between nocturnal blood pressure dipping and insulin resistance in children affected by NAFLD 62
T regulatory cell number and function: the autoimmune traits in liver diseases 62
null 62
NAFLD-non alcoholic fatty liver disease in overweight/obese child (ow/ob) born SGA (small for gestational age) 61
PNPLA3 I148M polymorphism and liver damage in obese children 61
Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal 61
Nonalcoholic fatty liver disease and atherosclerosis. 60
Fatty liver in adolescents: Mechanisms, clinical features and therapy 60
null 59
Liver fibrosis and therapeutic strategies: the goal for improving metabolism 59
null 58
Totale 7.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.429
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.429
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.793 0 0 0 0 0 446 700 516 523 276 181 151
2020/20211.196 108 165 49 45 20 45 23 96 172 179 75 219
2021/20222.498 20 96 212 153 378 171 50 296 219 150 183 570
2022/20231.896 514 297 29 177 204 298 24 96 163 13 57 24
2023/2024796 93 143 38 58 42 46 18 38 4 125 76 115
2024/2025734 139 74 69 76 154 222 0 0 0 0 0 0
Totale 13.932